SVB Securities Thinks Marinus’ Stock is Going to Recover

SVB Securities analyst Marc Goodman maintained a Buy rating on Marinus (MRNSResearch Report) on July 11 and set a price target of $27.00. The company’s shares closed last Friday at $5.87, close to its 52-week low of $3.97.

According to, Goodman is a 2-star analyst with an average return of 0.0% and a 46.2% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $29.60 average price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $16.82 and a one-year low of $3.97. Currently, Marinus has an average volume of 329.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Read More on MRNS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More